Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why

Oculis Holding AG (NASDAQ:OCS)’s share price gapped up prior to trading on Friday . The stock had previously closed at $18.70, but opened at $20.35. Oculis shares last traded at $20.41, with a volume of 64,061 shares changing hands.

Wall Street Analysts Forecast Growth

OCS has been the topic of several research reports. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Oculis in a research note on Monday, January 6th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Oculis presently has an average rating of “Buy” and an average price target of $28.80.

Oculis Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The firm has a market capitalization of $856.66 million, a price-to-earnings ratio of -10.96 and a beta of -0.33. The firm’s 50-day moving average price is $16.48 and its two-hundred day moving average price is $13.99.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.